Keenan JD, et al. – In this analysis of the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) trial, researchers determined whether each administration of azithromycin has a beneficiary or declining action towards antibiotic resistance in lowering post-neonatal childhood mortality. A total of 594 communities of children 1 to 59 months of age of the Niger component were assessed in both MORDOR I and II trials. Neither any additional serious adverse events nor enhanced effects caused by azithromycin during mass administration on childhood mortality in the third year of treatment were evident. Furthermore, in communities that had originally received placebo, childhood mortality decreased upon receiving azithromycin treatment.